Bengaluru: SKAN research trust and UK-based Quadram Institute Bioscience announced to undertake a study over the action of traditional medical compounds on bacteria, thereby aiding in the reformulation and development of novel antibacterial regimens, using TraDIS-Xpress platform.

The joint study ‘Application of TraDIS-Xpress in microbiology for healthy living’ is part of a larger Comprehensive Partnership Agreement between the two organisations that have ongoing international collaborations focused on gut health and developing gut microbial therapies to alleviate ageing and neurological diseases like parkinsons.

TraDIS-Xpress is Quadram’s proprietary genetic sequencing platform used to uncover new antimicrobial agents and develop better prebiotics and probiotics for health promotion.

As part of this study, the two partners are looking to generate data from large Indian cohorts that will aid in the development of India-specific therapies. Such data generation is also expected to hasten the TraDIS-Xpress platform’s development and amplify its applications’ scope.

Commenting over it Prof. Ian Charles, Director of Quadram Institute Bioscience, said, “Im excited to see the cutting-edge genomic technology and expertise we have here in Quadram supporting our valued partners at the SKAN Research Trust to benefit the health of the people of India, and also further our fundamental understanding of the links between microbes and human wellbeing.”

Providing further details Dr Yogesh Shouche, Deputy Director, SKAN, added, “The three-year project will also study the mechanisms of drug resistance for key pathogens relevant to India and the action of selected food additives used in India on the growth of selected gut microbes.”

  • Published On Jun 14, 2024 at 05:43 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App